The new BD Onclarity HPV test would enable patients to collect a sample without the need for liquids or other devices and mail it to the laboratory for testing.

Becton Dickinson (BDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The 15-minute digital lateral flow immunoassay originally obtained Emergency Use Authorization from the US FDA in 2020.

Now, the former chief operating officer has been tapped to be an executive vice president at Becton, Dickinson and Co. and ...

Becton, Dickinson and Company will release its third-quarter earnings next month, and analysts anticipate a single-digit ...

BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs FRANKLIN LAKES, N.J., July 23, 2025 / Biotech Newswire / -- BD (Becton, Dickinson ...

BD (NYSE:BDX) today announced the first pharma-sponsored combination product clinical trial using its wearable injector ...

Key Points Medtronic is closing in on Dividend King status and has a historically high yield.Becton, Dickinson is already a Dividend King and has a relatively high yield.Universal Health has a huge ...

Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” second quarter 2025 investor ...

Becton, Dickinson (NYSE:BDX) declares $1.04/share quarterly dividend, in line with previous. Forward yield 2.29% Payable Sept. 30; for shareholders of record Sept. 8; ex-div Sept. 8. See BDX Dividend ...

New CLIA-Waived Test Delivers Digital Results to Support Timely Clinical Decision-Making FRANKLIN LAKES, N.J., July 30, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) ...

Becton Dickinson & Co. closed 29.02% below its 52-week high of $251.99, which the company reached on February 3rd.